(function(){var loadHandler=window['sl_{5C30CC7C-43B9-4E83-9F5F-A086153E4BBA}'];loadHandler&&loadHandler(14, '<div id="spr0_52d5f0b"><div id="spr1_52d5f0b" class="kern"><img id="img3_52d5f0b" src="data/img3.png" width="960px" height="540px" alt="" style="left:0px;top:0px;"/><div id="spr3_52d5f0b" style="left:222.976px;top:165.764px;"><img id="img0_52d5f0b" src="data/img0.png" width="737" height="374" alt="" style="left:0.012px;top:0.118px;"/></div><div id="spr4_52d5f0b"><img id="img1_52d5f0b" src="data/img1.png" width="960" height="540" alt="" style="left:-0.084px;"/></div><div id="svg0_52d5f0b" style="left:0px;top:0px;"><svg width="76" height="540" viewBox="0 0 76 540"><path fill="#39302a" d="M0,0 h75.919 v540 h-75.919 Z"/></svg></div><div id="svg1_52d5f0b" style="left:75.751px;"><svg width="4" height="540" viewBox="0 0 4 540"><path fill="#9c6a6a" d="M0,0 h3.6 v540 h-3.6 Z"/></svg></div><div id="svg2_52d5f0b" style="left:79.093px;"><svg width="817" height="540" viewBox="0 0 817 540"><path fill="#39302a" fill-opacity="0.92" d="M0,0 h816.718 v540 h-816.718 Z"/></svg></div><div id="svg3_52d5f0b" style="left:895.853px;"><svg width="3" height="540" viewBox="0 0 3 540"><path fill="#9c6a6a" d="M0,0 h2.16 v540 h-2.16 Z"/></svg></div><div id="spr5_52d5f0b" style="left:172.83px;top:50.49px;"><div style="width:0px;"><span id="txt0_52d5f0b" class="relpos" style="left:9.575px;top:4.499px;"></span></div></div></div><div id="spr2_52d5f0b" class="kern"><div id="svg4_52d5f0b" style="left:699.304px;top:62.877px;"><svg width="134" height="51" viewBox="-0.375 -0.375 134 51"><path fill="none" stroke="#e5dedb" stroke-width="0.8" stroke-linecap="butt" stroke-linejoin="round" d="M0.375,0.375 h132.24 v49.238 h-132.24 Z"/></svg></div><div id="spr6_52d5f0b" style="left:699.679px;top:63.252px;"><div style="width:0px;"><span id="txt1_52d5f0b" class="relpos" style="left:12.075px;top:1.597px;">Results</span></div></div><div id="spr7_52d5f0b" style="left:144.973px;top:161.584px;"><div style="width:0px;"><span id="txt2_52d5f0b" class="nokern relpos" style="left:7.71px;top:21.923px;"></span><span id="txt3_52d5f0b" class="relpos" style="left:24.468px;top:19.443px;">The total follow-up time was 985.01 person- month, and the</span></div><div style="width:0px;"><span id="txt4_52d5f0b" class="relpos" style="left:34.35px;top:54.003px;">mortality rate was 83.72 per 100 person-month.</span></div><div style="width:0px;"><span id="txt5_52d5f0b" class="nokern relpos" style="left:7.71px;top:102.043px;"></span><span id="txt6_52d5f0b" class="relpos" style="left:24.468px;top:99.563px;">Incidence rate of group I vs. group II were 12.50 per 100 person-</span></div><div style="width:0px;"><span id="txt7_52d5f0b" class="relpos" style="left:34.35px;top:134.123px;">month and 6.40 per 100 person-month, respectively.</span></div><div style="width:0px;"><span id="txt8_52d5f0b" class="nokern relpos" style="left:7.71px;top:182.163px;"></span><span id="txt9_52d5f0b" class="relpos" style="left:24.468px;top:179.683px;">Median </span><span id="txt10_52d5f0b" class="relpos" style="left:24.463px;top:179.683px;">survival time </span><span id="txt11_52d5f0b" class="relpos" style="left:24.458px;top:179.683px;">were </span><span id="txt12_52d5f0b" class="relpos" style="left:24.453px;top:179.683px;">2.72 months</span><span id="txt13_52d5f0b" class="relpos" style="left:24.448px;top:179.683px;"> in group I </span><span id="txt14_52d5f0b" class="relpos" style="left:24.443px;top:179.683px;">vs.11.54</span></div><div style="width:0px;"><span id="txt15_52d5f0b" class="relpos" style="left:34.35px;top:214.243px;">months</span><span id="txt16_52d5f0b" class="relpos" style="left:34.345px;top:214.243px;"> in group II.</span></div></div><div id="spr8_52d5f0b"><img id="img2_52d5f0b" src="data/img2.png" width="446" height="70" alt="" style="left:0.219px;top:0.043px;"/></div></div></div>');})();